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point about this selection approach taken by Li and
coworkers is that the final screen for putative RNA bind-
ing dyes is indeed performed on living cells. Finally,
three library components were selected in the second-
ary screen (E36, E144 and F22) and notably E36, which
gave a positive reaction in the nucleoli staining screen,
was shown to be particularly highly selective for RNA.
Why are these fluorescent RNA binding dyes particu-
larly suitable for live cell studies? First, they are small
and cell membrane permeable. Therefore, they are rap-
idly and efficiently taken-up by cells when added to the
cell culture medium. This feature eliminates the need for
rather laborious microinjection procedures. Second, be-
cause of their small size, styryl dyes are expected to
have easy access to the various compartments within
a cell and to the RNA molecules that might be present
in those compartments. This is an important issue be-
cause there has always been some debate concerning
the accessibility of RNA molecules for dyes when they
are assembled in ribonucleoprotein complexes in their
native cellular environment. Third, the selected com-
pounds have their excitation and emission wavelength
in the visible range, are highly fluorescent, are photo-
stable, and show hardly any cytotoxicity and photo-
toxicity. These are all essential characteristics for live
cell imaging studies.
No doubt, RNA-specific fluorescent styryl dyes have
the potential to find wide application in research fields
related to cell biology. These innovative compounds
are particularly relevant in analysis of the dynamic prop-
erties of RNA localization in living cells. Furthermore, be-
cause various color variants can be selected, these dyes
can be easily applied in multicolor approaches by com-
bining them with dyes selective for other cellular compo-
nents like DNA.
Future studies may provide insight in the mechanism
by which styryl dyes bind to RNA. If a structural feature
or specific order of nucleotide sequence in the RNA
turns out to be involved in binding, it might then be pos-
sible to refine the selection procedure to select for library
components that bind specific types of RNAs; for exam-
ple, messenger RNAs, ribosomal RNAs, transfer RNAs
or small nuclear RNAs, or even specific gene transcripts.
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560Myxing It Up to Study
Chondramides
Considerable progress has been achieved in elucidat-
ing the biosynthesis of natural products with interest-
ing cellular targets. In this issueofChemistry&Biology,
Rachid et al. [1] provide a new example, taming genetic
manipulation of the producer of chondramide, an
actin-interfering compound.
Natural products (NPs) have provided a large number of
existing drugs and NPs, NP-derived, or NP-inspired
compounds represented over half of the drugs ap-
proved during the 1981–2002 period [2]. A large number
of NP-related compounds are also undergoing clinical
trials, particularly in the anti-infective and anticancerfields [3]. However, NP-based drug discovery has been
progressively abandoned by the pharmaceutical indus-
try during the last two decades. Two reasons have prob-
ably contributed to the declining interest in NPs as
potential drug leads: the labor-intensive nature of this
type of endeavor, and the expectation that genomics,
synthetic/combinatorial chemistry, and high throughput
screening can provide a sufficient number of drug leads.
This expectation has not been realized, and fewer drugs
are being approved despite spiraling R&D costs [4].
While large pharma was becoming disinterested in NP
research, the field attracted increasing attention from
many academic laboratories and biotech companies,
especially for the possibility of expanding NP diversity
through biology-based approaches, such as mutasyn-
thesis [5], combinatorial biosynthesis [6], or chemoenzy-
matic routes [7]. These approaches can complement
chemistry in expanding NP diversity. In order to
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561generate analogs of a particular NP, the biosynthetic
gene cluster must be available and the producing strain
genetically accessible.
Myxobacteria are valuable producers of secondary
metabolites, and many compounds interfering with eu-
karyotic cytoskeleton have been identified from them
[8]. While the diversity of their secondary metabolites
makes myxobacteria an interesting source of drug
leads, the strains are difficult to work with, and few lab-
oratories have mastered the skills necessary to handle
them [8]. In recent years, myxobacteria research has
gained momentum through the work of Rolf Mu¨ller’s
group, applying molecular genetics to secondary me-
tabolism within this order [9]. In the current issue of
Chemistry & Biology, Rachid et al. [1] describe the
gene cluster for the synthesis of the depsipeptide chon-
dramide in Chondromyces crocatus Cm5. This com-
pound interferes with actin, and appears to have the
same binding site as phalloidin, the well-known mush-
room toxin (see references in [1]). In contrast to phalloi-
din, chondramide effectively penetrates mammalian
cells, resulting in IC50 values in the low nanomolar range.
Despite the swarming properties of C. crocatus and
the paucity of selectable markers, Rachid et al. were
able to genetically access this strain through inter-
generic conjugation. This allowed them to establish
the cluster boundaries through gene knockouts and to
propose a biosynthetic pathway for the chondramides.
The authors noted several rare or unusual features in
the biosynthetic pathway as deduced from the chondra-
mide cluster, such as the presence of two adjacent acyl-
transferase domains in the second module of the PKS,
the occurrence of a likely tyrosine aminomutase, and
the lack of obvious candidates for hydroxylation and
O-methylation.
Despite the regularity of the pathways in secondary
metabolism, we should not be surprised to discover
‘‘exceptions to the rules.’’ Since the resulting com-
pounds are not strictly necessary for growth, producing
strains have probably had the opportunity to ‘‘mix and
match’’ genes and to experiment with different enzyme
systems for performing apparently identical chemical
reactions. Interestingly, the chondramides bear a strik-
ing similarity to jaspamide and related compounds iso-
lated from marine sponges, with which they also share
the same actin binding site. Thus, it may be that the
sponge metabolites are actually produced by bacterial
symbionts, as is increasingly being appreciated [10].
The work by Rachid et al. illustrates the amazing prog-
ress that can be made by using the genetics of second-
ary metabolism. The authors successfully applied an
almost ‘‘full package’’ of tools to a newly isolated gene
cluster from a hard-to-work-with strain: a gene transfer
system for the producing strain; gene knockouts; char-
acterization of domain specificity after expression in
E. coli; and production of fluorinated chondramides
after feeding fluorotryptophane to the producing strain.
However, further work is necessary before a suitable
production system can be made available for this class
of actin inhibitors. C. crocatus Cm5 is limited in this
respect as it has a 9 hr doubling time and produces
chondramides in low yield. Possibly, heterologous ex-
pression of the chondramide cluster may lead to greater
accessibility of chondramide and its derivatives [11].The current decade is witnessing the development of
a growing number of NP tools and the generation of ex-
citing information as a result. The last year has seen the
description of new strategies for NP-based focused
libraries [12], of novel groups of antibiotic-producing
actinomycets [13], of useful tailoring steps [14], the
structural elucidation of new classes of enzymes [15–
16], and the application of strategies for genome mining
[17], just to name a few. At the same time, new chemical
classes are being discovered from relatively common
microbial sources [18–19]. Therefore, despite a de-
creased industrial interest, NP research has never
been as active as today. In addition to providing impor-
tant insights into microbial ecology, physiology, and en-
zymology, some of these tools will eventually be applied
for discovering and developing new drugs. It is unlikely
that a single set of tools will prove of general applicabil-
ity. Instead, success may depend on choosing the
appropriate approach for the specific drug discovery
objective.
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